Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination…

By D. Roth, D. Nelson, A. Bruchfeld, Annmarie Liapakis, M. Silva, H. Monsour, Paul L. Martin, S. Pol, M. Londoño, T. Hassanein and 9 more. The Lancet, 2015

661 citations recorded by the source corpus.

Subfields: Hepatology, Infectious Diseases, Pharmacology

View Paper: https://www.semanticscholar.org/paper/605356c012299e9f757739325c46dcbf1963aab1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. A. Kim
2. Christoph Sarrazin
3. A. Aghemo
4. G. Dusheiko
5. M. Puoti
6. X. Forns
7. J. Pawlotsky

Citations in the corpus

• Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. (2018, methodology): “Elbasvir/grazoprevir and glecaprevir/ pibrentasvir are recommended regimens for patients with severe renal impairment or ESRD (see Table 3) based on C-SURFER [92] and EXPEDITION-4 [93] data, respectively.”
• EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, result): “The frequencies of renal system adverse events were comparable between treatment groups.(327) A real-world study using the same regimen in American patients with various stages of CKD showed similarly high SVR rates in patients infected with genotype 1b, regardless of the severity of renal disease.”
• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, background): “The frequencies of renal system adverse events were comparable between treatment groups.(184) The safety and efficacy data for the treatment phase of the deferred treatment group has been reported, with an SVR rate of 98% (97/99).”